2017

1. Effectiveness and safety of ombitasvir, paritaprevir, ritonavir ± dasabuvir ± ribavirin: An early access programme for Spanish patients with genotype 1/4 chronic hepatitis C virus infection

   Journal of Viral Hepatitis, Vol. 24, Núm. 3, pp. 226-237

2. Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for end-stage liver disease: Analysis of data from the Hepa-C registry

   Hepatology, Vol. 65, Núm. 6, pp. 1810-1822